SlideShare a Scribd company logo
Chapter 4
The Dose-Response
Relationship
Introduction
• The need to establish some criteria to base the relative safety of
chemicals is essential.
• Several methods are used to obtain data in order to establish safe
levels and provide information about the relative toxicity of
chemicals.
Acute Toxicological Studies (1)
• Information concerning the toxicity of a substance is obtained
primarily from either acute or chronic toxicity studies.
• Acute toxicity studies are the most commonly performed studies for
obtaining information on the effects of chemical exposure. They are
short-term, relatively inexpensive tests with death of the test animal
being the useful observed effect.
• Information obtained from acute toxicity tests can be used to
– determine the relative toxicity of different chemicals comparing the respective LD50
values, which are the doses that prove to be lethal for 50 percent of the test animals;
– identify the target organs (heart, liver, kidneys, etc.) that are affected as a result of
exposure; and
– determine the appropriate doses for long term, chronic studies.
Acute Toxicological Studies (2)
• To perform acute toxicity studies the test animal population is divided
into several groups, with an equal number of individuals (usually 10 to
50) in each group. One group of test animals –referred to as the
control group – is exposed to all the same experimental conditions
except exposure to the toxic substance.
• The groups are observed for 14 days, and the number of deaths in each
group is recorded.
Acute Toxicological Studies (3)
• LC50 is a measure of chemical toxicity resulting from inhalation. LC
means “lethal concentration” and the subscript has the same meaning as
described previous for LD. The unit of measure for the LC50 is usually
expressed as part per million (ppm).
Chronic Toxicological Studies (1)
• Chronic toxicity tests may be performed over a period of months, years,
or the lifetime of the test animal. Doses of the toxic substance are
selected to assure that most of the animals will survive the entire time
the study is performed.
• Different species of test animals may be more or less sensitive to the
same toxic chemical.
• Males and females of the same species may respond differently to the
same substance.
• Although acute and chronic studies provide useful information in
evaluating chemical toxicity, it is important to understand that they are
not truly representative of the environment to which people are exposed
in everyday life.
Chronic Toxicological Studies (2)
• Characteristics of animal studies
– A single dose
– A single route of exposure
– The number of animals exposed is small.
– The genetic make-up of the population is not very diverse.
– Only individuals in good health and/or of the same sex are selected.
• In reality
– Several different routes
– Exposure to more than one chemical at a time
– Greater genetic variability in a larger population – the range of
responses to a given chemicals more diverse.
– The collective interactive effect of all these factors on toxicity
makes it difficult to establish a cause-effect relationship.
Dose-Response Curves (1)
• The major purpose for performing acute and chronic toxicity studies is
to establish a cause-effect relationship between exposure to a toxic
substance and an observed effect in order to determine a safe exposure
level.
• A curve can be drawn that illustrates the relationship between the dose
administered and the observed response. This curve is referred to as
the dose-response curve.
• A dose-response curve can be developed form most chemicals. From
these curves the threshold level and the relative toxicity of chemicals can
be obtained to help establish safe levels of chemical exposure.
Dose-Response Curves (2)
• The threshold is the dose below which no effect is detected
or above which an effect is first observed.
• The threshold information is useful information in
extrapolating animal data to humans and calculating what
may be considered a safe human dose for a given toxic
substance.
• The threshold dose (ThD0.0) is measured as mg/kg/day. It
is assumed that humans are as sensitive as the test animal
used. To determine the equivalent dose in man the ThD0.0
is multiplied by the average weight of a man, which is
considered to be 70 kg.
Dose-Response Curves (3)
• The calculation used to determine the safe human dose
(SHD) is as follows:
substance
toxic
of
mg/day
Amount
SF
(kg)
70
ThD
SHD 0.0



Where
SHD = Safe Human Dose
ThD0.0 = Threshold dose at which no effect is observed.
70 Kg = Average weight of a man
SF = Safety factor (ranges from 10 to 1000, which varies
according to the type of test and data used to
obtain the ThD0.0.
Terminology Associated with
Dose-Response Curves (1)
• No observed effect level (NOEL)
– The highest tested dose of a substance that has been
reported to have no harmful (adverse) health effects on
people or animals.
• No observed adverse effect level (NOAEL)
– It denotes the level of exposure of an organism, found by
experiment or observation, at which there is no
biologically or statistically significant (e.g. alteration of
morphology, functional capacity, growth, development
or life span) increase in the frequency or severity of any
adverse effects in the exposed population when
compared to its appropriate control.
Terminology Associated with
Dose-Response Curves (2)
• lowest-observed-effect-level (LOEL)
– Lowest concentration or amount of a substance, found
by experiment or observation, that causes any alteration
in morphology, functional capacity, growth, development,
or life span of target organisms distinguishable from
normal (control) organisms of the same species and
strain under the same defined conditions of exposure
• lowest-observed-adverse-effect-level (LOAEL)
– Lowest concentration or amount of a substance, found
by experiment or observation, which causes an adverse
alteration of morphology, functional capacity, growth,
development, or life span of a target organism
distinguishable from normal (control) organisms of the
same species and strain under defined conditions of
exposure.
Terminology Associated with
Dose-Response Curves (3)
• Frank-effect level (FEL)
– Level of exposure that produces unmistakable and
irreversible effects (such as impairment or mortality)
at statistically significant increased severity or
frequency.
– The level where overt effects are observed is referred to
as the Frank-effect level.
Threshold Dose
• Dose below which no adverse effects are observable in a
population of exposed individuals.
• Threshold dose approximated by a NOAEL (No Observed
Adverse Effect Level)
Non-threshold Effects
• Thresholds are assumed not to exist for genotoxic
carcinogens
Safe Dose for Threshold Effect
• NOAEL approach
– Identify the adverse effect that occurs at the lowest dose
– Determine the NOAEL or LOAEL for that endpoint
– Divide NOAEL/LOAEL by uncertainty factors
Acceptable Daily Intake
• ADI estimated (maximum) amount of an agent, expressed
on a body mass basis, to which a subject may be exposed
over his lifetime without appreciable health risk (also TDI,
tolerable daily intake)
• ADI derived from NOAEL by the use of uncertainty
factors UFs (or safety factors SFs)
Reference Dose (RfD)
• RfD is an estimate of the daily exposure that is likely
to be without appreciable health effect even if
continued exposure occurs over a lifetime.
Uncertainty Factors
• Default values:
UFinterspecies = 10 , UFhuman variability = 10
Additional Uncertainty Factors
• Sometimes applied:
– UFLOAEL-NOAEL = 3 or 10
– UFsubchronic-chronic = 3 or 10
– UF database insufficiences = up to 10
• MF, modifying factor for professional judgement: up
to 10
• RfD = NOAEL (or LOAEL) / UF1 UF2 UF3 MF
Benchmark Dose Approach (1)
• NOAEL approach uses only single points, shape of
dose-response is ignored.
• Bench mark dose (BMD) is calculated from the curve
fitted to the dose-reponse data, so all information is
used.
• BMD can only be used when available data are
suitable for modelling.
• Not replacement for NOAEL, but additional tool
Benchmark Dose Approach (2)
1. A mathematical model is applied to the
experimental data to produce a dose-response curve
of best fit.
2. By statistical calculation an upper 95% confidence
limit of the curve is determined
3. The Benchmark Response is defined as 10% (or 5%,
or 1%).
4. The Benchmark Dose corresponds to the bench
mark response on the upper confidence limit curve.
Benchmark Dose Approach (3)
Non-threshold?
• Absence of a detectable effect at low doses is either
because the dose is below a threshold or because the
response is below the level that can be detected by the
test sytem.
Threshold or Non-threshold
• Presence of a threshold cannot be proven from
experimental data.
• Conclusions about existence of a threshold are based
on biological plausibility and expert judgement.
• Genotoxic effects (DNA dammage leading to cancer)
are thought to be possible at any level of exposure, so
no threshold.
Low-dose Extrapolation
• Dose-response curve is use to extrapolate to doses lower
than then the experimental region.
Calculated Risk or Safe Dose
• Extrapolation may be used to calculate:
– the risk associated with a known intake.
– intake associated with a de minimis risk, e.g. an
increased life time risk of developing cancer of 1
in 106 (‘virtually safe dose’, VSD).
Linear Low-dose Extrapolation
• Assumption: linear relationship between dose and
biological response
Linear Extrapolation from LED10
• LED10
– low confidence limit of dose with response of 10%
From LED10 to VSD
• If LED10 = 57 mg/kg/day (response 10% or 0,1)
• then VSD (virtual safe dose, response 1 in 106 or 10-6)
= 57 x 10-6 / 0,1 = 5,7 x 10-4 mg/kg/day
ALARA Approach
• For genotoxic carcinogens (non-threshold effects)
also the ALARA-approach may be followed:
exposure to be reduced to as low as reasonably
achievable (ALARA) or as low as reasonably
practical (ALARP)
Relative Toxicity (1)
• A comparison of the dose-response curves for two or more different
chemicals – administered to the same type of test animal – can be used
to determine the relative toxicity of the chemicals.
• The LD50 for chemical A is less than the LD50 for chemical B.
Therefore, chemical A is considered more toxic than chemical B.
Relative Toxicity (2)
• Chemical A is more toxic than chemical B at the higher
doses, but at the lower doses chemical B is more toxic than
chemical A.
Relative Toxicity (3)
• Relative toxicity also be evaluated by comparing the slope
of each dose-response curve. A steep dose-response curve
is indicative of a chemical that is rapidly and extensively
absorbed and slowly detoxified: therefore, the chemical is
more toxic.
Variables Influencing Toxicity
• These factors include:
– the dose-time relationship,
– the route of exposure,
– the physical and chemical properties of the toxic substance,
– the chemical interactions,
– the interspecies and intraspecies variability,
– genetics,
– age,
– sex, and
– health of the individual collectively.
• The toxicity of a given substance is the net result of the
complex interaction between all of these various factors.
Dose-Time Relationship
• Not only is the dose of a toxic substance important in
determining toxicity, but so is the frequency and length of
exposure.
• The rapid elimination of the substance from the blood
stream decreases the probability of an adverse effect.
• Gradual accumulation increases the probability that an
adverse effect will occur.
– Symptoms of acute exposure to sublethal quantities of chlorinated
solvents, such as chloroform or carbon tetrachloride, are primarily
associated with the nervous system, such as excitability, dizziness
and narcosis.
– Chronic exposure to these solvents is primarily associated with
liver damage.
Routes of Exposure
• LD50 values for various organochlorine and
organophosphate pesticides resulting from ingestion and
skin exposure.
• The different absorption rates for various regions of the
skin in the human male
Physical and Chemical Factors
• Chemical toxicity can be affected by the arrangement of
the atoms in a molecule.
• The structural differences can result in different toxic
effects being observed as a result of exposure.
– The LD50 for 1,1-dichloroethylene is 5,750 mg/kg and the LD50 for
the 1,2-dichloroethylene isomers is 770 mg/kg.
– Based on animal studies, 1,1-dichloroethylene is a suspected human
carcinogen. Its structure is similar to a known human carcinogen,
vinyl chloride.
– The 1,2-dichloroethylene isomers are not carcinogenic, but they do
have different effects. The cis isomer is an irritant and acts as a
narcotic (causes drowsiness). The trans isomer affects the central
nervous system (brain and spinal cord) and the gastrointestinal
system causing weakness, tremors, cramps, nausea; it may also
cause liver and kidney damage.
Interspecies and Intraspecies Variability
• Interspecies variability
– The variability in response between species is primarily the result
of the evolution of different biological mechanisms involved in the
metabolism of toxic substances.
– The differences in toxicity may be due to the rate at which
metabolism occurs, or whether metabolism produces chemical
intermediates more toxic than the parent compound.
• For example, the pesticide malathion is metabolized at a different rate in
mammals than in insects. In mammals, the chemical intermediates are rapidly
metabolized to deliver end products that are excreted from the body. In insects
metabolize malathion more slowly and produce a chemical intermediate ---
malaoxon --- that is toxic to the insect.
• Methanol intoxication results in ocular damage and blindness. However, in
other species methanol is less toxic and the symptoms associated with human
intoxication are not observed.
• Rats do not have a vomiting reflex. Rodenticides, such as squill, are more
effective if they are ingested because the rat can not discard the substance by
vomiting.
Intraspecies (individual) variability
• Individuals within a population ---exposed to a single dose
--- will demonstrate a wide array of responses.
• This type of variability can be caused by differences
associated with individual genetics and sex of the
individuals within the population.
Genetics
• The differences in genetics makeup both within species and
between species markedly influence the disposition and the
metabolism of toxic substances.
– For example, some individuals have an enzyme (glucose-6-
phosphate dehydrogenase) deficiency resulting in their red blood
cells being more fragile than normal. Consequently, red blood cells
of these individuals are more susceptible to chemicals such as
phenylhydrazine and primaquine, which cause hemolysis.
– The enzyme aryl hydrocarbon hydroxylase (AHH) transforms the
chemical benzo[a]pyrene to its carcinogenic metabolite. Some
individuals produce lower amounts of AHH; benzo[a]pyrene is
therefore less toxic to these individuals. Similarly, low AHH
individuals may be less likely to develop cancer from cigarette
smoke.
Age
• In general, younger and developing individuals are more
sensitive to toxic substances than older individuals. The
difference can be primarily attributed to differences in
metabolisms; specially to differences in the functioning of
the liver.
• In younger individuals the mechanisms for detoxifying
substances are less developed than in older individuals.
However, some substances are less toxic to the young than
to adults.
• The lead absorption rate is four to five times greater in
young individuals than in adults; the cadmium absorption
rate is 20 times greater than in adults.
Sex
• The difference in toxicity between genders seems to be
primarily influence by the sex hormones (estrogen and
testosterone), which can affect metabolism.
• Some organophosphate pesticides are more toxic to
females than males.
– Parathion is metabolized more rapidly in females resulting in a
higher concentration of the more toxic intermediate, paraoxon.
– Male rats are 10 times more susceptible to liver damage than
female rats as a result of chronic oral exposure to DDT.
State of Health
• The liver and the kidney are important organs for
detoxifying and removing toxic substances. Therefore,
conditions that lead to liver or kidney disease enhance the
toxic effects of substances normally detoxified by these
organs.
Chemical Interactions (1)
• The interaction between two or more chemicals and their
subsequent effects have not been widely studied; not
because these interactions are not important, but rather
because the results are difficult to interpret and
extrapolate, and also because the studies are longer and
costlier.
• The presence of other chemicals at the time of exposure or
as a result of previous exposure can affect the response to
the specific toxicant being studied. These effects can be
additive, synergistic, antagonistic, or they may
demonstrate the characteristics associated with
sensitization or potentiation
Chemical Interactions (2)
• Additive effects
– An additive effect occurs when the combined effect of
the two chemicals is equal to the sum of the effects of
each individual chemical.
• Synergistic effect
– A synergistic effect occurs when the observed effects are
greater than what would be predicted by simply
summing the effects of each individual chemical.
Chemical Interactions (3)
• Antagonistic effects
– Antagonistic effects are the basis on which antidotes are
developed to counteract the effects of toxic substances
that enter the body.
– Antagonistic effects occur when the sum of the effects of
each individual chemical is less than the sum of the
effects for both chemicals.
Chemical Interactions (4)
• Four major types of antagonism
– Functional antagonism
• It refers to a type of reaction two chemicals have on a specific
physiological function in the test organism, usually producing
counterbalancing or opposite effects.
– Chemical antagonism
• It may be referred to as chemical inactivation. This type of
interaction is the result of a reaction between two chemicals to
produces a less toxic product.
– Dispositional antagonism
• The toxic substance is either transformed into a less toxic
substance or it is eliminated from the body more rapidly, then
the observed effects will be less than the expected ones.
Chemical Interactions (5)
– Receptor antagonism
• It occurs when two chemicals require binding to the same
receptor in order to exert their effect. The result is that when
the two chemicals are administered together the observed effect
is less than the sum of the effects for each chemical.
– Sensitization
• Initial exposure to toxic chemicals does not always result in an
observable or measurable effect. However, subsequent
exposure to the same chemical may result in an observable or
measurable effect.
• Sensitization occurs as a result of the interaction of the body’s
immune system with the toxic chemical during the initial
exposure.
Chemical Interactions (6)
– Potentiation
• At first glance it would appear that synergism and potentiation
are the same. In A potentiation, only one of the chemicals has
an observable effect when administered alone.
• Chemical A has no effect on mortality (0%). Chemical B
causes 25% mortality. When the two chemicals are
administered together the effect is greater than the sum of their
individual effects (0% + 25% = 100 %).
LD50 of
Chemicals
Substance Animal, Route LD50 Reference
Sucrose (table sugar) rat, oral 29,700,000,000 ng/kg [7]
Vitamin C (ascorbic acid) rat, oral 11,900,000,000 ng/kg [8]
Grain alcohol (ethanol) rat, oral 7,060,000,000 ng/kg [10]
Melamine rat, oral 6,000,000,000 ng/kg
Table Salt rat, oral 3,000,000,000 ng/kg [12]
Paracetamol (acetaminophen) rat, oral 1,944,000,000 ng/kg [13]
Metallic Arsenic rat, oral 763,000,000 ng/kg [15]
Aspirin (acetylsalicylic acid) rat, oral 200,000,000 ng/kg [17]
Caffeine rat, oral 192,000,000 ng/kg [18]
Cadmium oxide rat, oral 72,000,000 ng/kg [22]
Nicotine rat, oral 50,000,000 ng/kg [23]
Strychnine rat, oral 16,000,000 ng/kg [24]
Arsenic trioxide rat, oral 14,000,000 ng/kg [25]
Metallic Arsenic rat, intraperitoneal 13,000,000 ng/kg [26]
Sodium cyanide rat, oral 6,400,000 ng/kg [27]
Beryllium oxide rat, oral 500,000 ng/kg [30]
Aflatoxin B1 (from Aspergillus flavus) rat, oral 480,000 ng/kg [31]
Dioxin (TCDD) rat, oral 20,000 ng/kg [33]
Polonium-210 human, inhalation 10 ng/kg (estimated) [37]
Botulinum toxin (Botox)
human, oral,
injection, inhalation
1 ng/kg (estimated) [38]
Ionizing radiation human, irradiation 6 Gy
Typical Costs of Various Types of Toxicity Tests
Typical Testing protocols for Acute and Chronic
Toxicity Studies
Dose-Response Curve
LD50 Values of Organochlorine Pesticides
LD50 Values of Organophosphate Pesticides
Regional Differences of Dermal Absorption in Human Male
Toxicity of various Compounds to
Different Test Species
No-effect Levels on
a Dose-Response Curve
Acute Toxicity of N-hydroxy
acetylaminofluorene in Various Strains of Rats
Five Threshold Doses
• 美國環境保護署(EPA)對動物毒性實驗的反應程度確立了五種界限值(threshold),
用以評估毒性強弱而發展出各類毒性物質的每日允許攝取量。這五個界限值為:
• 一 ﹑沒有可觀察到的影響值(no-observed-effect level,NOEL)。
• 二﹑沒有可觀察到的不良影響值(no-observed-adverse-effect level,NOAEL)。
• 三﹑可觀察到有影響的最低值(lowest-observed-adverse-drrect level,LOEL)。
• 四﹑可觀察到有不良影響的最低值(lowest-observed-adverse-effect level,LOAEL)。
• 五﹑有直接顯著影響值(frank effect level,FEL)。
• 美國是以NOAEL值經過體重權衡後,除以安全因素而得到每日允許攝取量。而這一限
值就是表示,對設定毒性物質可允許它每天進入體內之總和量。
•
•
圖片連結-各種劑量反應關係 各種劑量反應關係 圖片連結-各種劑量反應關係
LOEL
• 最低作用值(LOEL,Lowest-observed effect level)
• 是指在研究人體或動物接觸某種物質時產生任何反應的頻率或嚴重性在生物學上顯著
增加的最低劑量。 相關名詞
• 最低作用值:不良效應級(有害作用劑量):最低濃度或數量的物質,通過實驗或觀察
發現,這會導致不利的改變形態,機能,生長,發育,壽命或生物體的目標分辨正常
(對照)的生物物種和同一菌株在規定條件下的暴露。 逆轉錄不利影響 , 最低的觀察
效果級別 , 不遵守,不利的效應級別 , 無觀測效應水平
• 在劑量反應曲線中,我們常常會應用到幾個相關名詞,包括:
• 無反應劑量(no-effect level, NEL)或無觀察反應劑量(no-observed effect level, NOEL
):無顯著反應的最低劑量。
• 最低觀察反應劑量 (最低作用值)lowest observed effect level,LOEL):可以觀察到反應
之最低劑量,不過此反應為次要之反應而非引起主要想要測量之反應。
• 無觀察危害反應劑量(no observed adverse effectlevel, NOAEL):一些非欲觀察之毒性
反應(危害性低)發生之劑量,但在高劑量下觀察得到的反應,在此劑量並不會出現
。 (無顯著危害的最高劑量,並非無反應而是與對照組無統計差異)
• 最低觀察危害反應劑量(lowest observed adverseeffect level, LOAEL):第一個可以觀
察得到危害反應的最低劑量濃度。
• 法蘭克反應劑量(frank effect level, FEL):引起嚴重危害反應發生之劑量稱之。 訂定

More Related Content

What's hot

Platinum analogs
Platinum analogsPlatinum analogs
Platinum analogs
LAKSHMI DEEPTHI GEDELA
 
ecotoxicology
ecotoxicologyecotoxicology
ecotoxicology
tharamttc
 
Environmental toxicology
Environmental toxicologyEnvironmental toxicology
Environmental toxicology
Cenderawasih Univercity
 
Toxicokinetics
ToxicokineticsToxicokinetics
Toxicokineticsraj kumar
 
Introduction to toxicology
 Introduction to toxicology  Introduction to toxicology
Introduction to toxicology
Ratnabro
 
Presentation on mass spectroscopy
Presentation on mass spectroscopyPresentation on mass spectroscopy
Presentation on mass spectroscopy
smita shelke
 
Toxic responses of solvents and vapours
Toxic responses of solvents and vapoursToxic responses of solvents and vapours
Toxic responses of solvents and vapours
Koppala RVS Chaitanya
 
Polycyclic aromatic hydrocarbons and their effects on the environment
Polycyclic aromatic hydrocarbons and their effects on the environmentPolycyclic aromatic hydrocarbons and their effects on the environment
Polycyclic aromatic hydrocarbons and their effects on the environment
Dipo Elegbs
 
Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)
Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)
Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)
AkshayYadav176
 
Classes of Toxic Chemicals and Their Effects
Classes of Toxic Chemicals and Their EffectsClasses of Toxic Chemicals and Their Effects
Classes of Toxic Chemicals and Their Effects
Shoaibe H T Shefat
 
Basics of QSAR Modeling
Basics of QSAR ModelingBasics of QSAR Modeling
Basics of QSAR Modeling
Prachi Pradeep
 
Platinum salts presentation
Platinum salts presentationPlatinum salts presentation
Platinum salts presentationmadurai
 
Absorption, distribution, metabolism & elimination
Absorption, distribution, metabolism & eliminationAbsorption, distribution, metabolism & elimination
Absorption, distribution, metabolism & elimination
Asif Yahya
 
Pop presentation
Pop presentationPop presentation
Pop presentation
Irfan Youngman
 
Mass spectrometry
Mass spectrometryMass spectrometry
Chapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitorsChapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitors
Nilesh Kucha
 
Environmental Toxicology
Environmental ToxicologyEnvironmental Toxicology
Environmental Toxicology
GAURAV. H .TANDON
 
Concepts of toxicology
Concepts of toxicologyConcepts of toxicology
Concepts of toxicology
Govt.college,Nagda, ujjain.M.P
 
Different route of exposure of toxicant
Different route of exposure of toxicantDifferent route of exposure of toxicant
Different route of exposure of toxicantAngel Al-hamad
 

What's hot (20)

Platinum analogs
Platinum analogsPlatinum analogs
Platinum analogs
 
ecotoxicology
ecotoxicologyecotoxicology
ecotoxicology
 
Environmental toxicology
Environmental toxicologyEnvironmental toxicology
Environmental toxicology
 
Toxicokinetics
ToxicokineticsToxicokinetics
Toxicokinetics
 
Introduction to toxicology
 Introduction to toxicology  Introduction to toxicology
Introduction to toxicology
 
Presentation on mass spectroscopy
Presentation on mass spectroscopyPresentation on mass spectroscopy
Presentation on mass spectroscopy
 
Ebook ecotoxicology chapter1
Ebook  ecotoxicology chapter1Ebook  ecotoxicology chapter1
Ebook ecotoxicology chapter1
 
Toxic responses of solvents and vapours
Toxic responses of solvents and vapoursToxic responses of solvents and vapours
Toxic responses of solvents and vapours
 
Polycyclic aromatic hydrocarbons and their effects on the environment
Polycyclic aromatic hydrocarbons and their effects on the environmentPolycyclic aromatic hydrocarbons and their effects on the environment
Polycyclic aromatic hydrocarbons and their effects on the environment
 
Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)
Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)
Pharmacophore Mapping and Virtual Screening (Computer aided Drug design)
 
Classes of Toxic Chemicals and Their Effects
Classes of Toxic Chemicals and Their EffectsClasses of Toxic Chemicals and Their Effects
Classes of Toxic Chemicals and Their Effects
 
Basics of QSAR Modeling
Basics of QSAR ModelingBasics of QSAR Modeling
Basics of QSAR Modeling
 
Platinum salts presentation
Platinum salts presentationPlatinum salts presentation
Platinum salts presentation
 
Absorption, distribution, metabolism & elimination
Absorption, distribution, metabolism & eliminationAbsorption, distribution, metabolism & elimination
Absorption, distribution, metabolism & elimination
 
Pop presentation
Pop presentationPop presentation
Pop presentation
 
Mass spectrometry
Mass spectrometryMass spectrometry
Mass spectrometry
 
Chapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitorsChapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitors
 
Environmental Toxicology
Environmental ToxicologyEnvironmental Toxicology
Environmental Toxicology
 
Concepts of toxicology
Concepts of toxicologyConcepts of toxicology
Concepts of toxicology
 
Different route of exposure of toxicant
Different route of exposure of toxicantDifferent route of exposure of toxicant
Different route of exposure of toxicant
 

Similar to Doses.pdf

Basics of Toxicology & Its role in Drug development-12-01-24.pdf
Basics of Toxicology & Its role in Drug development-12-01-24.pdfBasics of Toxicology & Its role in Drug development-12-01-24.pdf
Basics of Toxicology & Its role in Drug development-12-01-24.pdf
mohanathakkar
 
Mey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," HarvardMey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," Harvard
Mey Akashah
 
Pharmacology -II(5 Unit)
Pharmacology -II(5 Unit)Pharmacology -II(5 Unit)
Pharmacology -II(5 Unit)
KhawajaAmtulRaoufQaz
 
Animal Toxicity Studies
Animal Toxicity StudiesAnimal Toxicity Studies
Animal Toxicity Studies
KartickMahaldar1
 
Extrapolation.pptx
Extrapolation.pptxExtrapolation.pptx
Extrapolation.pptx
Sushobhan Roy
 
MMM PPT.pptx
MMM PPT.pptxMMM PPT.pptx
MMM PPT.pptx
ArifUddin60
 
Discriptive toxicology
Discriptive toxicologyDiscriptive toxicology
Discriptive toxicology
Dnyaneshwari Pande
 
MRL(Minimal Risk Level)
MRL(Minimal Risk Level)MRL(Minimal Risk Level)
MRL(Minimal Risk Level)
BENITA SAKLANI MAINDOLA
 
Toxicity testing
Toxicity testingToxicity testing
Toxicity testing
Jaineel Dharod
 
Modeling Dose Response for Risk Assessment, George Gray
Modeling Dose Response for Risk Assessment, George GrayModeling Dose Response for Risk Assessment, George Gray
Modeling Dose Response for Risk Assessment, George Gray
OECD Governance
 
TOXICOPHARMACOLOGY.pdf
TOXICOPHARMACOLOGY.pdfTOXICOPHARMACOLOGY.pdf
TOXICOPHARMACOLOGY.pdf
RAMDAS BHAT
 
Extrapolation of in vitro data to preclinical and.pptx
Extrapolation of in vitro data to preclinical and.pptxExtrapolation of in vitro data to preclinical and.pptx
Extrapolation of in vitro data to preclinical and.pptx
ARSHIKHANAM4
 
First dose size in humans and non linear pharmacokinetics.pptx
First dose size in humans and non linear pharmacokinetics.pptxFirst dose size in humans and non linear pharmacokinetics.pptx
First dose size in humans and non linear pharmacokinetics.pptx
ABDULRAUF411
 
Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)
MuhammadImranulhaq3
 
Basic definition and types of toxicology
Basic definition and types of toxicologyBasic definition and types of toxicology
Basic definition and types of toxicology
AbhishekJoshi312
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
Urmila Aswar
 
Oecd guidelines
Oecd guidelinesOecd guidelines
Oecd guidelines
Umangi Thakkar
 
FST 507.ppt
FST 507.pptFST 507.ppt
FST 507.ppt
Ernest Bonah, Ph.D
 
FST 507.ppt
FST 507.pptFST 507.ppt
FST 507.ppt
Ernest Bonah, Ph.D
 
FST 507.ppt
FST 507.pptFST 507.ppt
FST 507.ppt
Ernest Bonah, Ph.D
 

Similar to Doses.pdf (20)

Basics of Toxicology & Its role in Drug development-12-01-24.pdf
Basics of Toxicology & Its role in Drug development-12-01-24.pdfBasics of Toxicology & Its role in Drug development-12-01-24.pdf
Basics of Toxicology & Its role in Drug development-12-01-24.pdf
 
Mey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," HarvardMey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," Harvard
 
Pharmacology -II(5 Unit)
Pharmacology -II(5 Unit)Pharmacology -II(5 Unit)
Pharmacology -II(5 Unit)
 
Animal Toxicity Studies
Animal Toxicity StudiesAnimal Toxicity Studies
Animal Toxicity Studies
 
Extrapolation.pptx
Extrapolation.pptxExtrapolation.pptx
Extrapolation.pptx
 
MMM PPT.pptx
MMM PPT.pptxMMM PPT.pptx
MMM PPT.pptx
 
Discriptive toxicology
Discriptive toxicologyDiscriptive toxicology
Discriptive toxicology
 
MRL(Minimal Risk Level)
MRL(Minimal Risk Level)MRL(Minimal Risk Level)
MRL(Minimal Risk Level)
 
Toxicity testing
Toxicity testingToxicity testing
Toxicity testing
 
Modeling Dose Response for Risk Assessment, George Gray
Modeling Dose Response for Risk Assessment, George GrayModeling Dose Response for Risk Assessment, George Gray
Modeling Dose Response for Risk Assessment, George Gray
 
TOXICOPHARMACOLOGY.pdf
TOXICOPHARMACOLOGY.pdfTOXICOPHARMACOLOGY.pdf
TOXICOPHARMACOLOGY.pdf
 
Extrapolation of in vitro data to preclinical and.pptx
Extrapolation of in vitro data to preclinical and.pptxExtrapolation of in vitro data to preclinical and.pptx
Extrapolation of in vitro data to preclinical and.pptx
 
First dose size in humans and non linear pharmacokinetics.pptx
First dose size in humans and non linear pharmacokinetics.pptxFirst dose size in humans and non linear pharmacokinetics.pptx
First dose size in humans and non linear pharmacokinetics.pptx
 
Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)Et lect 8 indices of toxicology (1)
Et lect 8 indices of toxicology (1)
 
Basic definition and types of toxicology
Basic definition and types of toxicologyBasic definition and types of toxicology
Basic definition and types of toxicology
 
OECD Guidelines
OECD GuidelinesOECD Guidelines
OECD Guidelines
 
Oecd guidelines
Oecd guidelinesOecd guidelines
Oecd guidelines
 
FST 507.ppt
FST 507.pptFST 507.ppt
FST 507.ppt
 
FST 507.ppt
FST 507.pptFST 507.ppt
FST 507.ppt
 
FST 507.ppt
FST 507.pptFST 507.ppt
FST 507.ppt
 

More from Prof. Dr Pharmacology

4- Biochemistry_2-Glycogen Metabolism.ppt
4- Biochemistry_2-Glycogen Metabolism.ppt4- Biochemistry_2-Glycogen Metabolism.ppt
4- Biochemistry_2-Glycogen Metabolism.ppt
Prof. Dr Pharmacology
 
Anthelmintics and Antiprotozoal medications.ppt
Anthelmintics and Antiprotozoal medications.pptAnthelmintics and Antiprotozoal medications.ppt
Anthelmintics and Antiprotozoal medications.ppt
Prof. Dr Pharmacology
 
ANTIPROTOZOALs.ppt
ANTIPROTOZOALs.pptANTIPROTOZOALs.ppt
ANTIPROTOZOALs.ppt
Prof. Dr Pharmacology
 
EXPECTORANT.pdf
EXPECTORANT.pdfEXPECTORANT.pdf
EXPECTORANT.pdf
Prof. Dr Pharmacology
 
Scabies.pptx
Scabies.pptxScabies.pptx
Scabies.pptx
Prof. Dr Pharmacology
 
ANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.pptANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.ppt
Prof. Dr Pharmacology
 
Antimicrobials.ppt
Antimicrobials.pptAntimicrobials.ppt
Antimicrobials.ppt
Prof. Dr Pharmacology
 
Skeletal S_Axial Division.pdf
Skeletal S_Axial Division.pdfSkeletal S_Axial Division.pdf
Skeletal S_Axial Division.pdf
Prof. Dr Pharmacology
 
ANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.pptANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.ppt
Prof. Dr Pharmacology
 
ANTIHELMINTHICs.ppt
ANTIHELMINTHICs.pptANTIHELMINTHICs.ppt
ANTIHELMINTHICs.ppt
Prof. Dr Pharmacology
 
CVS_Lecture 2.pdf
CVS_Lecture 2.pdfCVS_Lecture 2.pdf
CVS_Lecture 2.pdf
Prof. Dr Pharmacology
 
CNS_Lecture4.pdf
CNS_Lecture4.pdfCNS_Lecture4.pdf
CNS_Lecture4.pdf
Prof. Dr Pharmacology
 
CNS_Lecture5.pdf
CNS_Lecture5.pdfCNS_Lecture5.pdf
CNS_Lecture5.pdf
Prof. Dr Pharmacology
 
introtopharmacology-101213190521-phpapp02 (1).pdf
introtopharmacology-101213190521-phpapp02 (1).pdfintrotopharmacology-101213190521-phpapp02 (1).pdf
introtopharmacology-101213190521-phpapp02 (1).pdf
Prof. Dr Pharmacology
 
introductiontopharmacology-180925200753.pdf
introductiontopharmacology-180925200753.pdfintroductiontopharmacology-180925200753.pdf
introductiontopharmacology-180925200753.pdf
Prof. Dr Pharmacology
 

More from Prof. Dr Pharmacology (20)

4- Biochemistry_2-Glycogen Metabolism.ppt
4- Biochemistry_2-Glycogen Metabolism.ppt4- Biochemistry_2-Glycogen Metabolism.ppt
4- Biochemistry_2-Glycogen Metabolism.ppt
 
Anthelmintics and Antiprotozoal medications.ppt
Anthelmintics and Antiprotozoal medications.pptAnthelmintics and Antiprotozoal medications.ppt
Anthelmintics and Antiprotozoal medications.ppt
 
cough.pdf
cough.pdfcough.pdf
cough.pdf
 
EXPECTORANT.pdf
EXPECTORANT.pdfEXPECTORANT.pdf
EXPECTORANT.pdf
 
DRC.pdf
DRC.pdfDRC.pdf
DRC.pdf
 
ANTIPROTOZOALs.ppt
ANTIPROTOZOALs.pptANTIPROTOZOALs.ppt
ANTIPROTOZOALs.ppt
 
EXPECTORANT.pdf
EXPECTORANT.pdfEXPECTORANT.pdf
EXPECTORANT.pdf
 
cough.pdf
cough.pdfcough.pdf
cough.pdf
 
Scabies.pptx
Scabies.pptxScabies.pptx
Scabies.pptx
 
ANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.pptANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.ppt
 
Antimicrobials.ppt
Antimicrobials.pptAntimicrobials.ppt
Antimicrobials.ppt
 
Skeletal S_Axial Division.pdf
Skeletal S_Axial Division.pdfSkeletal S_Axial Division.pdf
Skeletal S_Axial Division.pdf
 
ANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.pptANTIPROTOZOAL DRUGS.ppt
ANTIPROTOZOAL DRUGS.ppt
 
ANTIHELMINTHICs.ppt
ANTIHELMINTHICs.pptANTIHELMINTHICs.ppt
ANTIHELMINTHICs.ppt
 
CVS_Lecture 2.pdf
CVS_Lecture 2.pdfCVS_Lecture 2.pdf
CVS_Lecture 2.pdf
 
CNS_Lecture4.pdf
CNS_Lecture4.pdfCNS_Lecture4.pdf
CNS_Lecture4.pdf
 
CNS_Lecture5.pdf
CNS_Lecture5.pdfCNS_Lecture5.pdf
CNS_Lecture5.pdf
 
Drugs.pdf
Drugs.pdfDrugs.pdf
Drugs.pdf
 
introtopharmacology-101213190521-phpapp02 (1).pdf
introtopharmacology-101213190521-phpapp02 (1).pdfintrotopharmacology-101213190521-phpapp02 (1).pdf
introtopharmacology-101213190521-phpapp02 (1).pdf
 
introductiontopharmacology-180925200753.pdf
introductiontopharmacology-180925200753.pdfintroductiontopharmacology-180925200753.pdf
introductiontopharmacology-180925200753.pdf
 

Recently uploaded

micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 

Recently uploaded (20)

micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 

Doses.pdf

  • 2. Introduction • The need to establish some criteria to base the relative safety of chemicals is essential. • Several methods are used to obtain data in order to establish safe levels and provide information about the relative toxicity of chemicals.
  • 3. Acute Toxicological Studies (1) • Information concerning the toxicity of a substance is obtained primarily from either acute or chronic toxicity studies. • Acute toxicity studies are the most commonly performed studies for obtaining information on the effects of chemical exposure. They are short-term, relatively inexpensive tests with death of the test animal being the useful observed effect. • Information obtained from acute toxicity tests can be used to – determine the relative toxicity of different chemicals comparing the respective LD50 values, which are the doses that prove to be lethal for 50 percent of the test animals; – identify the target organs (heart, liver, kidneys, etc.) that are affected as a result of exposure; and – determine the appropriate doses for long term, chronic studies.
  • 4. Acute Toxicological Studies (2) • To perform acute toxicity studies the test animal population is divided into several groups, with an equal number of individuals (usually 10 to 50) in each group. One group of test animals –referred to as the control group – is exposed to all the same experimental conditions except exposure to the toxic substance. • The groups are observed for 14 days, and the number of deaths in each group is recorded.
  • 5. Acute Toxicological Studies (3) • LC50 is a measure of chemical toxicity resulting from inhalation. LC means “lethal concentration” and the subscript has the same meaning as described previous for LD. The unit of measure for the LC50 is usually expressed as part per million (ppm).
  • 6. Chronic Toxicological Studies (1) • Chronic toxicity tests may be performed over a period of months, years, or the lifetime of the test animal. Doses of the toxic substance are selected to assure that most of the animals will survive the entire time the study is performed. • Different species of test animals may be more or less sensitive to the same toxic chemical. • Males and females of the same species may respond differently to the same substance. • Although acute and chronic studies provide useful information in evaluating chemical toxicity, it is important to understand that they are not truly representative of the environment to which people are exposed in everyday life.
  • 7. Chronic Toxicological Studies (2) • Characteristics of animal studies – A single dose – A single route of exposure – The number of animals exposed is small. – The genetic make-up of the population is not very diverse. – Only individuals in good health and/or of the same sex are selected. • In reality – Several different routes – Exposure to more than one chemical at a time – Greater genetic variability in a larger population – the range of responses to a given chemicals more diverse. – The collective interactive effect of all these factors on toxicity makes it difficult to establish a cause-effect relationship.
  • 8. Dose-Response Curves (1) • The major purpose for performing acute and chronic toxicity studies is to establish a cause-effect relationship between exposure to a toxic substance and an observed effect in order to determine a safe exposure level. • A curve can be drawn that illustrates the relationship between the dose administered and the observed response. This curve is referred to as the dose-response curve. • A dose-response curve can be developed form most chemicals. From these curves the threshold level and the relative toxicity of chemicals can be obtained to help establish safe levels of chemical exposure.
  • 9. Dose-Response Curves (2) • The threshold is the dose below which no effect is detected or above which an effect is first observed. • The threshold information is useful information in extrapolating animal data to humans and calculating what may be considered a safe human dose for a given toxic substance. • The threshold dose (ThD0.0) is measured as mg/kg/day. It is assumed that humans are as sensitive as the test animal used. To determine the equivalent dose in man the ThD0.0 is multiplied by the average weight of a man, which is considered to be 70 kg.
  • 10. Dose-Response Curves (3) • The calculation used to determine the safe human dose (SHD) is as follows: substance toxic of mg/day Amount SF (kg) 70 ThD SHD 0.0    Where SHD = Safe Human Dose ThD0.0 = Threshold dose at which no effect is observed. 70 Kg = Average weight of a man SF = Safety factor (ranges from 10 to 1000, which varies according to the type of test and data used to obtain the ThD0.0.
  • 11. Terminology Associated with Dose-Response Curves (1) • No observed effect level (NOEL) – The highest tested dose of a substance that has been reported to have no harmful (adverse) health effects on people or animals. • No observed adverse effect level (NOAEL) – It denotes the level of exposure of an organism, found by experiment or observation, at which there is no biologically or statistically significant (e.g. alteration of morphology, functional capacity, growth, development or life span) increase in the frequency or severity of any adverse effects in the exposed population when compared to its appropriate control.
  • 12. Terminology Associated with Dose-Response Curves (2) • lowest-observed-effect-level (LOEL) – Lowest concentration or amount of a substance, found by experiment or observation, that causes any alteration in morphology, functional capacity, growth, development, or life span of target organisms distinguishable from normal (control) organisms of the same species and strain under the same defined conditions of exposure • lowest-observed-adverse-effect-level (LOAEL) – Lowest concentration or amount of a substance, found by experiment or observation, which causes an adverse alteration of morphology, functional capacity, growth, development, or life span of a target organism distinguishable from normal (control) organisms of the same species and strain under defined conditions of exposure.
  • 13. Terminology Associated with Dose-Response Curves (3) • Frank-effect level (FEL) – Level of exposure that produces unmistakable and irreversible effects (such as impairment or mortality) at statistically significant increased severity or frequency. – The level where overt effects are observed is referred to as the Frank-effect level.
  • 14. Threshold Dose • Dose below which no adverse effects are observable in a population of exposed individuals. • Threshold dose approximated by a NOAEL (No Observed Adverse Effect Level)
  • 15. Non-threshold Effects • Thresholds are assumed not to exist for genotoxic carcinogens
  • 16. Safe Dose for Threshold Effect • NOAEL approach – Identify the adverse effect that occurs at the lowest dose – Determine the NOAEL or LOAEL for that endpoint – Divide NOAEL/LOAEL by uncertainty factors
  • 17. Acceptable Daily Intake • ADI estimated (maximum) amount of an agent, expressed on a body mass basis, to which a subject may be exposed over his lifetime without appreciable health risk (also TDI, tolerable daily intake) • ADI derived from NOAEL by the use of uncertainty factors UFs (or safety factors SFs)
  • 18. Reference Dose (RfD) • RfD is an estimate of the daily exposure that is likely to be without appreciable health effect even if continued exposure occurs over a lifetime.
  • 19. Uncertainty Factors • Default values: UFinterspecies = 10 , UFhuman variability = 10
  • 20. Additional Uncertainty Factors • Sometimes applied: – UFLOAEL-NOAEL = 3 or 10 – UFsubchronic-chronic = 3 or 10 – UF database insufficiences = up to 10 • MF, modifying factor for professional judgement: up to 10 • RfD = NOAEL (or LOAEL) / UF1 UF2 UF3 MF
  • 21. Benchmark Dose Approach (1) • NOAEL approach uses only single points, shape of dose-response is ignored. • Bench mark dose (BMD) is calculated from the curve fitted to the dose-reponse data, so all information is used. • BMD can only be used when available data are suitable for modelling. • Not replacement for NOAEL, but additional tool
  • 22. Benchmark Dose Approach (2) 1. A mathematical model is applied to the experimental data to produce a dose-response curve of best fit. 2. By statistical calculation an upper 95% confidence limit of the curve is determined 3. The Benchmark Response is defined as 10% (or 5%, or 1%). 4. The Benchmark Dose corresponds to the bench mark response on the upper confidence limit curve.
  • 24. Non-threshold? • Absence of a detectable effect at low doses is either because the dose is below a threshold or because the response is below the level that can be detected by the test sytem.
  • 25. Threshold or Non-threshold • Presence of a threshold cannot be proven from experimental data. • Conclusions about existence of a threshold are based on biological plausibility and expert judgement. • Genotoxic effects (DNA dammage leading to cancer) are thought to be possible at any level of exposure, so no threshold.
  • 26. Low-dose Extrapolation • Dose-response curve is use to extrapolate to doses lower than then the experimental region.
  • 27. Calculated Risk or Safe Dose • Extrapolation may be used to calculate: – the risk associated with a known intake. – intake associated with a de minimis risk, e.g. an increased life time risk of developing cancer of 1 in 106 (‘virtually safe dose’, VSD).
  • 28. Linear Low-dose Extrapolation • Assumption: linear relationship between dose and biological response
  • 29. Linear Extrapolation from LED10 • LED10 – low confidence limit of dose with response of 10%
  • 30. From LED10 to VSD • If LED10 = 57 mg/kg/day (response 10% or 0,1) • then VSD (virtual safe dose, response 1 in 106 or 10-6) = 57 x 10-6 / 0,1 = 5,7 x 10-4 mg/kg/day
  • 31. ALARA Approach • For genotoxic carcinogens (non-threshold effects) also the ALARA-approach may be followed: exposure to be reduced to as low as reasonably achievable (ALARA) or as low as reasonably practical (ALARP)
  • 32. Relative Toxicity (1) • A comparison of the dose-response curves for two or more different chemicals – administered to the same type of test animal – can be used to determine the relative toxicity of the chemicals. • The LD50 for chemical A is less than the LD50 for chemical B. Therefore, chemical A is considered more toxic than chemical B.
  • 33. Relative Toxicity (2) • Chemical A is more toxic than chemical B at the higher doses, but at the lower doses chemical B is more toxic than chemical A.
  • 34. Relative Toxicity (3) • Relative toxicity also be evaluated by comparing the slope of each dose-response curve. A steep dose-response curve is indicative of a chemical that is rapidly and extensively absorbed and slowly detoxified: therefore, the chemical is more toxic.
  • 35. Variables Influencing Toxicity • These factors include: – the dose-time relationship, – the route of exposure, – the physical and chemical properties of the toxic substance, – the chemical interactions, – the interspecies and intraspecies variability, – genetics, – age, – sex, and – health of the individual collectively. • The toxicity of a given substance is the net result of the complex interaction between all of these various factors.
  • 36. Dose-Time Relationship • Not only is the dose of a toxic substance important in determining toxicity, but so is the frequency and length of exposure. • The rapid elimination of the substance from the blood stream decreases the probability of an adverse effect. • Gradual accumulation increases the probability that an adverse effect will occur. – Symptoms of acute exposure to sublethal quantities of chlorinated solvents, such as chloroform or carbon tetrachloride, are primarily associated with the nervous system, such as excitability, dizziness and narcosis. – Chronic exposure to these solvents is primarily associated with liver damage.
  • 37. Routes of Exposure • LD50 values for various organochlorine and organophosphate pesticides resulting from ingestion and skin exposure. • The different absorption rates for various regions of the skin in the human male
  • 38. Physical and Chemical Factors • Chemical toxicity can be affected by the arrangement of the atoms in a molecule. • The structural differences can result in different toxic effects being observed as a result of exposure. – The LD50 for 1,1-dichloroethylene is 5,750 mg/kg and the LD50 for the 1,2-dichloroethylene isomers is 770 mg/kg. – Based on animal studies, 1,1-dichloroethylene is a suspected human carcinogen. Its structure is similar to a known human carcinogen, vinyl chloride. – The 1,2-dichloroethylene isomers are not carcinogenic, but they do have different effects. The cis isomer is an irritant and acts as a narcotic (causes drowsiness). The trans isomer affects the central nervous system (brain and spinal cord) and the gastrointestinal system causing weakness, tremors, cramps, nausea; it may also cause liver and kidney damage.
  • 39. Interspecies and Intraspecies Variability • Interspecies variability – The variability in response between species is primarily the result of the evolution of different biological mechanisms involved in the metabolism of toxic substances. – The differences in toxicity may be due to the rate at which metabolism occurs, or whether metabolism produces chemical intermediates more toxic than the parent compound. • For example, the pesticide malathion is metabolized at a different rate in mammals than in insects. In mammals, the chemical intermediates are rapidly metabolized to deliver end products that are excreted from the body. In insects metabolize malathion more slowly and produce a chemical intermediate --- malaoxon --- that is toxic to the insect. • Methanol intoxication results in ocular damage and blindness. However, in other species methanol is less toxic and the symptoms associated with human intoxication are not observed. • Rats do not have a vomiting reflex. Rodenticides, such as squill, are more effective if they are ingested because the rat can not discard the substance by vomiting.
  • 40. Intraspecies (individual) variability • Individuals within a population ---exposed to a single dose --- will demonstrate a wide array of responses. • This type of variability can be caused by differences associated with individual genetics and sex of the individuals within the population.
  • 41. Genetics • The differences in genetics makeup both within species and between species markedly influence the disposition and the metabolism of toxic substances. – For example, some individuals have an enzyme (glucose-6- phosphate dehydrogenase) deficiency resulting in their red blood cells being more fragile than normal. Consequently, red blood cells of these individuals are more susceptible to chemicals such as phenylhydrazine and primaquine, which cause hemolysis. – The enzyme aryl hydrocarbon hydroxylase (AHH) transforms the chemical benzo[a]pyrene to its carcinogenic metabolite. Some individuals produce lower amounts of AHH; benzo[a]pyrene is therefore less toxic to these individuals. Similarly, low AHH individuals may be less likely to develop cancer from cigarette smoke.
  • 42. Age • In general, younger and developing individuals are more sensitive to toxic substances than older individuals. The difference can be primarily attributed to differences in metabolisms; specially to differences in the functioning of the liver. • In younger individuals the mechanisms for detoxifying substances are less developed than in older individuals. However, some substances are less toxic to the young than to adults. • The lead absorption rate is four to five times greater in young individuals than in adults; the cadmium absorption rate is 20 times greater than in adults.
  • 43. Sex • The difference in toxicity between genders seems to be primarily influence by the sex hormones (estrogen and testosterone), which can affect metabolism. • Some organophosphate pesticides are more toxic to females than males. – Parathion is metabolized more rapidly in females resulting in a higher concentration of the more toxic intermediate, paraoxon. – Male rats are 10 times more susceptible to liver damage than female rats as a result of chronic oral exposure to DDT.
  • 44. State of Health • The liver and the kidney are important organs for detoxifying and removing toxic substances. Therefore, conditions that lead to liver or kidney disease enhance the toxic effects of substances normally detoxified by these organs.
  • 45. Chemical Interactions (1) • The interaction between two or more chemicals and their subsequent effects have not been widely studied; not because these interactions are not important, but rather because the results are difficult to interpret and extrapolate, and also because the studies are longer and costlier. • The presence of other chemicals at the time of exposure or as a result of previous exposure can affect the response to the specific toxicant being studied. These effects can be additive, synergistic, antagonistic, or they may demonstrate the characteristics associated with sensitization or potentiation
  • 46. Chemical Interactions (2) • Additive effects – An additive effect occurs when the combined effect of the two chemicals is equal to the sum of the effects of each individual chemical. • Synergistic effect – A synergistic effect occurs when the observed effects are greater than what would be predicted by simply summing the effects of each individual chemical.
  • 47. Chemical Interactions (3) • Antagonistic effects – Antagonistic effects are the basis on which antidotes are developed to counteract the effects of toxic substances that enter the body. – Antagonistic effects occur when the sum of the effects of each individual chemical is less than the sum of the effects for both chemicals.
  • 48. Chemical Interactions (4) • Four major types of antagonism – Functional antagonism • It refers to a type of reaction two chemicals have on a specific physiological function in the test organism, usually producing counterbalancing or opposite effects. – Chemical antagonism • It may be referred to as chemical inactivation. This type of interaction is the result of a reaction between two chemicals to produces a less toxic product. – Dispositional antagonism • The toxic substance is either transformed into a less toxic substance or it is eliminated from the body more rapidly, then the observed effects will be less than the expected ones.
  • 49. Chemical Interactions (5) – Receptor antagonism • It occurs when two chemicals require binding to the same receptor in order to exert their effect. The result is that when the two chemicals are administered together the observed effect is less than the sum of the effects for each chemical. – Sensitization • Initial exposure to toxic chemicals does not always result in an observable or measurable effect. However, subsequent exposure to the same chemical may result in an observable or measurable effect. • Sensitization occurs as a result of the interaction of the body’s immune system with the toxic chemical during the initial exposure.
  • 50. Chemical Interactions (6) – Potentiation • At first glance it would appear that synergism and potentiation are the same. In A potentiation, only one of the chemicals has an observable effect when administered alone. • Chemical A has no effect on mortality (0%). Chemical B causes 25% mortality. When the two chemicals are administered together the effect is greater than the sum of their individual effects (0% + 25% = 100 %).
  • 51. LD50 of Chemicals Substance Animal, Route LD50 Reference Sucrose (table sugar) rat, oral 29,700,000,000 ng/kg [7] Vitamin C (ascorbic acid) rat, oral 11,900,000,000 ng/kg [8] Grain alcohol (ethanol) rat, oral 7,060,000,000 ng/kg [10] Melamine rat, oral 6,000,000,000 ng/kg Table Salt rat, oral 3,000,000,000 ng/kg [12] Paracetamol (acetaminophen) rat, oral 1,944,000,000 ng/kg [13] Metallic Arsenic rat, oral 763,000,000 ng/kg [15] Aspirin (acetylsalicylic acid) rat, oral 200,000,000 ng/kg [17] Caffeine rat, oral 192,000,000 ng/kg [18] Cadmium oxide rat, oral 72,000,000 ng/kg [22] Nicotine rat, oral 50,000,000 ng/kg [23] Strychnine rat, oral 16,000,000 ng/kg [24] Arsenic trioxide rat, oral 14,000,000 ng/kg [25] Metallic Arsenic rat, intraperitoneal 13,000,000 ng/kg [26] Sodium cyanide rat, oral 6,400,000 ng/kg [27] Beryllium oxide rat, oral 500,000 ng/kg [30] Aflatoxin B1 (from Aspergillus flavus) rat, oral 480,000 ng/kg [31] Dioxin (TCDD) rat, oral 20,000 ng/kg [33] Polonium-210 human, inhalation 10 ng/kg (estimated) [37] Botulinum toxin (Botox) human, oral, injection, inhalation 1 ng/kg (estimated) [38] Ionizing radiation human, irradiation 6 Gy
  • 52. Typical Costs of Various Types of Toxicity Tests
  • 53. Typical Testing protocols for Acute and Chronic Toxicity Studies
  • 55. LD50 Values of Organochlorine Pesticides
  • 56. LD50 Values of Organophosphate Pesticides
  • 57. Regional Differences of Dermal Absorption in Human Male
  • 58. Toxicity of various Compounds to Different Test Species
  • 59. No-effect Levels on a Dose-Response Curve
  • 60. Acute Toxicity of N-hydroxy acetylaminofluorene in Various Strains of Rats
  • 61. Five Threshold Doses • 美國環境保護署(EPA)對動物毒性實驗的反應程度確立了五種界限值(threshold), 用以評估毒性強弱而發展出各類毒性物質的每日允許攝取量。這五個界限值為: • 一 ﹑沒有可觀察到的影響值(no-observed-effect level,NOEL)。 • 二﹑沒有可觀察到的不良影響值(no-observed-adverse-effect level,NOAEL)。 • 三﹑可觀察到有影響的最低值(lowest-observed-adverse-drrect level,LOEL)。 • 四﹑可觀察到有不良影響的最低值(lowest-observed-adverse-effect level,LOAEL)。 • 五﹑有直接顯著影響值(frank effect level,FEL)。 • 美國是以NOAEL值經過體重權衡後,除以安全因素而得到每日允許攝取量。而這一限 值就是表示,對設定毒性物質可允許它每天進入體內之總和量。 • • 圖片連結-各種劑量反應關係 各種劑量反應關係 圖片連結-各種劑量反應關係
  • 62. LOEL • 最低作用值(LOEL,Lowest-observed effect level) • 是指在研究人體或動物接觸某種物質時產生任何反應的頻率或嚴重性在生物學上顯著 增加的最低劑量。 相關名詞 • 最低作用值:不良效應級(有害作用劑量):最低濃度或數量的物質,通過實驗或觀察 發現,這會導致不利的改變形態,機能,生長,發育,壽命或生物體的目標分辨正常 (對照)的生物物種和同一菌株在規定條件下的暴露。 逆轉錄不利影響 , 最低的觀察 效果級別 , 不遵守,不利的效應級別 , 無觀測效應水平 • 在劑量反應曲線中,我們常常會應用到幾個相關名詞,包括: • 無反應劑量(no-effect level, NEL)或無觀察反應劑量(no-observed effect level, NOEL ):無顯著反應的最低劑量。 • 最低觀察反應劑量 (最低作用值)lowest observed effect level,LOEL):可以觀察到反應 之最低劑量,不過此反應為次要之反應而非引起主要想要測量之反應。 • 無觀察危害反應劑量(no observed adverse effectlevel, NOAEL):一些非欲觀察之毒性 反應(危害性低)發生之劑量,但在高劑量下觀察得到的反應,在此劑量並不會出現 。 (無顯著危害的最高劑量,並非無反應而是與對照組無統計差異) • 最低觀察危害反應劑量(lowest observed adverseeffect level, LOAEL):第一個可以觀 察得到危害反應的最低劑量濃度。 • 法蘭克反應劑量(frank effect level, FEL):引起嚴重危害反應發生之劑量稱之。 訂定